Table 3 Summary statistics for empirical Bayes pharmacokinetic parameter estimates on study day 1, analysed by course

From: Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – a study of the United Kingdom Children's Cancer Study Group

Parameter

Course

N

Mean

s.d.

Min

Median

Max

CL/F (l h−1)

2

26

20.7

16.7

4.8

17.8

80.8

 

4

12

12.5

6.7

3.4

11.1

24.7

 

6

10

13.2

6.9

7.1

10.9

30.7

V/F (l)

2

26

121.1

128.7

21.6

75.0

490.2

 

4

12

40.9

22.1

13.2

38.2

100.3

 

6

10

68.8

57.2

30.1

41.4

194.4

AUC (μmol h l−1)

2

26

13.2

9.0

2.1

10.5

37.3

 

4

12

20.8

11.0

6.1

20.2

43.7

 

6

10

17.2

8.1

5.4

15.8

31.3

CL/F (l h−1 m−2)

2

26

31.9

27.2

7.7

24.0

136.2

 

4

12

17.7

11.4

5.9

13.4

41.0

 

6

10

19.1

12.4

7.6

15.8

51.2

V/F (l m−2)

2

26

177.4

173.7

29.7

125.7

662.7

 

4

12

58.8

39.7

21.7

51.3

168.3

 

6

10

100.5

94.9

34.0

55.6

324.5

LAG (min)

2

26

41.2

10.6

23.7

39.0

57.7

 

4

12

49.4

7.8

37.8

52.5

62.5

 

6

10

43.7

7.5

31.9

44.1

54.5

  1. CL/F, apparent clearance; LAG, absorption lag time; AUC, area under the curve, extrapolated to infinity; N, number of patients studied on each course of treatment. CL/F and V/F also given as values corrected for body surface area.
  2. Course 2 refers to first available course. This was course 1 in 5 patients and course 3 in one patient.
Back to article page